IRIS PubliCatt

De Cristofaro, Raimondo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.891
NA - Nord America 3.620
AS - Asia 1.307
AF - Africa 27
SA - Sud America 13
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 8
Totale 8.877
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.591
DE - Germania 1.327
SE - Svezia 801
CN - Cina 582
UA - Ucraina 455
IT - Italia 330
SG - Singapore 304
IE - Irlanda 228
FR - Francia 186
GB - Regno Unito 150
ID - Indonesia 146
IN - India 129
PL - Polonia 120
FI - Finlandia 107
RU - Federazione Russa 94
TR - Turchia 38
HK - Hong Kong 29
CA - Canada 24
BE - Belgio 21
IR - Iran 21
JP - Giappone 20
NL - Olanda 17
AU - Australia 10
CI - Costa d'Avorio 10
KR - Corea 9
RO - Romania 9
VN - Vietnam 8
CH - Svizzera 7
CZ - Repubblica Ceca 7
EG - Egitto 6
MK - Macedonia 6
BR - Brasile 5
ES - Italia 5
LT - Lituania 5
AT - Austria 4
EU - Europa 4
ZA - Sudafrica 4
A2 - ???statistics.table.value.countryCode.A2??? 3
IL - Israele 3
IQ - Iraq 3
NO - Norvegia 3
TN - Tunisia 3
AR - Argentina 2
BD - Bangladesh 2
DZ - Algeria 2
GR - Grecia 2
KW - Kuwait 2
LV - Lettonia 2
MX - Messico 2
PE - Perù 2
PR - Porto Rico 2
TH - Thailandia 2
VE - Venezuela 2
A1 - Anonimo 1
AM - Armenia 1
BO - Bolivia 1
CL - Cile 1
HR - Croazia 1
HU - Ungheria 1
LU - Lussemburgo 1
MO - Macao, regione amministrativa speciale della Cina 1
MU - Mauritius 1
MY - Malesia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
PH - Filippine 1
PT - Portogallo 1
QA - Qatar 1
RS - Serbia 1
SA - Arabia Saudita 1
SC - Seychelles 1
SY - Repubblica araba siriana 1
TW - Taiwan 1
Totale 8.877
Salva come PNG Salva come JPEG
Città #
Chandler 657
Ashburn 342
Jacksonville 248
Singapore 232
Dublin 220
San Mateo 212
Nanjing 157
Jakarta 142
Wilmington 138
Ann Arbor 112
Warsaw 104
Woodbridge 98
Dearborn 88
New York 88
Boston 87
Fairfield 77
Milan 75
Moscow 75
Houston 72
Lawrence 71
Redwood City 71
Pune 70
Nürnberg 65
Seattle 58
Beijing 57
Princeton 55
Cattolica 53
Nanchang 52
Marseille 45
Redmond 44
Chicago 38
Izmir 34
Los Angeles 34
University Park 33
Bremen 32
Munich 32
Hangzhou 29
Kunming 27
Rome 26
Mountain View 25
Augusta 23
Changsha 22
Hong Kong 22
Norwalk 22
Boardman 21
Shenyang 21
Brussels 18
Detroit 18
London 18
Bareggio 17
Hebei 17
Helsinki 16
Jiaxing 16
Tianjin 16
Zhengzhou 16
Cambridge 15
Kraków 14
Shanghai 14
Padova 13
Leawood 12
Abidjan 10
Andover 10
Chengdu 10
Hefei 10
Hounslow 10
Lanzhou 10
Southend 10
Fremont 9
Jinan 9
Paris 8
San Diego 8
Guangzhou 7
Lancaster 7
Ardabil 6
Frankfurt am Main 6
Phoenix 6
Prilep 6
Seoul 6
Toronto 6
Zurich 6
Busto Arsizio 5
Edinburgh 5
Kish 5
Menlo Park 5
Ningbo 5
Ottawa 5
Simi Valley 5
Tokyo 5
Washington 5
Brno 4
Dong Ket 4
Falls Church 4
Forest City 4
Gurgaon 4
Hanoi 4
Indiana 4
Millbury 4
Philadelphia 4
San Francisco 4
Sydney 4
Totale 4.775
Salva come PNG Salva come JPEG
Nome #
Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment 278
Qualitative and quantitative modifications of von willebrand factor in patients with essential thrombocythemia and controlled platelet count 269
The oxidative modification of von Willebrand factor is associated with thrombotic angiopathies in diabetes mellitus. 266
Pathogenesis Of Portal Vein Thrombosis In Liver Cirrhosis: The Role of the ADAMTS13/VWF Unbalance 232
Novel path to IL-6 trans-signaling through thrombin-induced soluble IL-6 receptor release by platelets 151
Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development 131
Glycaemic variability affects ischaemia-induced angiogenesis in diabetic mice. 127
The Type 2b P.R1306w Natural Mutation Of Von Willebrand Factor Dramatically Enhances The Multimer Sensitivity To Shear Stress 124
Prostaglandin E2 differentially modulates human platelet function through the prostanoid EP2 and EP3 receptors 122
Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13. A new prothrombotic mechanism associated with oxidative stress 118
An old drug for a new application: carbazochrome-sodium-sulfonate in HHT 107
Effect of fibrinogen concentration on the velocity of platelet aggregation. 105
Pseudo-acquired vWD in essential thrombocythemia: the role of platelets 105
Cyclooxygenase-2 (COX-2) inhibition constrains indoleamine 2,3-dioxygenase 1 (IDO1) activity in acute myeloid leukaemia cells 102
The D173G mutation in ADAMTS-13 causes a severe form of congenital thrombotic thrombocytopenic purpura. A clinical, biochemical and in silico study 102
Evaluation of the thiobarbituric acid test (TBA test) properties for the determination of glycosylated hemoglobins by comparison with chromatography and isoelectrofocusing. 100
Oxidized von Willebrand factor is efficiently cleaved by serine proteases from primary granules of leukocytes: divergence from adamts-13 99
Hyposialylation of neprilysin possibly affects its expression and enzymatic activity in hereditary inclusion-body myopathy muscle 98
β2-Glycoprotein I Binds Thrombin and Selectively Inhibits the Enzyme Procoagulant Functions 98
Congenital prothrombin deficiency: an update 92
Kinetic study of von Willebrand factor self-aggregation induced by ristocetin 89
Structural and funtional mapping of the thrombin domain involved in the binding to the platelet glycoprotein Ib 88
Presence of portal vein thrombosis in liver cirrhosis is strongly associated with low levels of ADAMTS-13: a pilot study 88
ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study 88
Aims: The ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation (ORIGAMI) study investigates the safety and efficacy of Edoxaban administered via PEG in patients with atrial fibrillation and a clinical indication for a long-term anticoagulation. Design: In this prospective, single-centre observational study, 12 PEG-treated patients with indication to anticoagulation will receive edoxaban via PEG and will be followed up to 6 months. Plasma antifactor Xa activity and edoxaban concentrations will be assessed. Thromboembolic (ischaemic stroke, systemic embolism, venous thromboembolism) and bleeding events (Bleeding Academic Research Consortium and Thrombolysis in Myocardial Infarction) will be recorded at 1 and 6 months. Preliminary results: A retrospective analysis of five atrial fibrillation cases undergoing PEG implantation at our Institution who received edoxaban via PEG showed plasma anti-FXa levels at a steady state of 146 ± 15 ng/ml, without major adverse event at a mean follow-up of 6 months. Conclusion: ORIGAMI prospectively investigates PEG-administration of edoxaban in PEG-treated patients requiring long-term anticoagulation. Our preliminary retrospective data support this route of DOAC administration. 82
Increased platelet-fibrinogen affinity in patients with myeloproliferative disorders. 81
Hexopeptidase high performance liquid chromatography (HPLC) mapping and is application to peptide sequence strategies. 80
PURIFICATION OF THE ISOLATED BETA-CHAIN OF ADULT HUMAN-HEMOGLOBIN FROM ITS POST-TRANSLATIONAL MODIFICATION 78
Defective platelet responsiveness to thrombin and protease-activated receptors agonists in a novel case of gray platelet syndrome: correlation between the platelet defect and the alpha-granule content in the patient and four relatives 78
Direct oral anticoagulants and therapeutic adherence: do not let your guard down 77
high performance liquid chromatography in protein sequence determination. 76
Homocysteinemia is inversely correlated with platelet count and inversely correlated with sE-and sP-selectin levels in females homozygous for C677T methylenetetrahydrofolate reductase 74
Evaluation of assay methods to measure plasma ADAMTS13 activity in thrombotic microangiopathies. 74
Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects 74
Haemostatic system in inflammatory bowel diseases: new players in gut inflammation. 73
Biochemical properties of indoleamine 2,3-dioxygenase: from structure to optimized design of inhibitors 73
On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens 71
Portal vein thrombosis occurrence in a cirrhotic patient during treatment with rivaroxaban 71
Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects. 71
Carbamazepine interaction with direct oral anticoagulants: help from the laboratory for the personalized management of oral anticoagulant therapy 71
Immune toilerance by intermittent factor VIII boluses in two hemophilia A patients 70
SPONTANEOUS DEEP HEMATOMAS IN 2 PATIENTS WITH MYELOFIBROSIS - EVIDENCE OF PLATELET MEMBRANE GLYCOPROTEIN MODIFICATIONS 70
The effect of shear stress on protein conformation: Physical forces operating on biochemical systems: The case of von Willebrand factor. 70
Hemophilia A and von Willebrand deficiency: therapeutic implications 70
ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study 70
Detection of Platelet-Activating Antibodies Associated with Vaccine-Induced Thrombotic Thrombocytopenia by Flow Cytometry: An Italian Experience 70
Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: impact on mediators and mechanisms of the inflammatory response 69
Does chronic oral anticoagulation reduce in-hospital mortality among COVID-19 older patients? 69
Allosteric equilibria in the binding reaction of fibrinogen to platelets. 68
Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma 68
Placental-derived PGI2 inhibits cord blood platelet function 67
Another family with IGPS 67
Proteolytic Processing of Von Willebrand Factor by Adamts13 and Leukocyte Proteases 67
Carbamazepine interaction with direct oral anticoagulants: help from the laboratory for the personalized management of oral anticoagulant therapy 67
Inherited macrothrombocytopenia with distinctive platelet ultrastructural and functional features 66
β2 -Glycoprotein I binds to thrombin and selectively inhibits the enzyme procoagulant functions 66
Diagnosis and management of cerebral venous sinus thrombosis in children: a single-center retrospective analysis 66
Thrombin-thrombomodulin interaction: energetics and potential role of water as an allosteric effector. 64
Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma 64
Noncanonical type 2B von Willebrand disease associated with mutations in the VWF D9D3 and D4 domains 64
Relevance of chloride binding to von Willebrand factor in type 2B von Willebrand disease patients 63
Placental derived PGI2 inhibits cord platelet function:possible role of PGI in THR transient hyporeactivity of newborn platelets 63
From angiotensin-converting enzyme 2 disruption to thromboinflammatory microvascular disease: A paradigm drawn from COVID-19 63
The dominant-negative von Willebrand factor gene deletion p.P1127_C1948delinsR: molecular mechanism and modulation. 62
Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: effects on platelet function in the systemic circulation and across the filter 62
The expanding spectrum of PRPS1-associated phenotypes: three novel mutations segregating with X-linked hearing loss and mild peripheral neuropathy 62
Congenital prothrombin deficiency 61
High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism 61
Plasma protein oxidation is associated with an increase of procoagulant markers causing an imbalance between pro- and anticoagulant pathways in healthy subjects 60
A recurrent Gly43Asp substitution in coagulation Factor X rigidifies its catalytic pocket and impairs catalytic activity and intracellular trafficking 60
Ristocetin-induced self-aggregation of von Willebrand factor. 58
Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients 57
Mechanistic studies on ADAMTS13 catalysis. 57
Wiskott-Aldrich syndrome: report of an autosomal dominant variant 57
Apixaban Interacts with Haemoglobin: Effects on Its Plasma Levels 57
Oral anticoagulants in fragile patients with percutaneous endoscopic gastrostomy and atrial fibrillation: the ORIGAMI pilot investigation 57
The linkage between binding of the C-terminal domain of hirudin and amidase activity in human alpha-thrombin 56
INHIBITION OF FIBRINOGEN BINDING TO HUMAN-PLATELETS BY BLOCKAGE OF NA+/H+ EXCHANGE. 56
Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE survey 55
Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: effects on platelet function in the systemic circulation and across the filter 55
Mechanochemistry of von Willebrand factor 55
Carbon monoxyde and oxygen binding to human hemoglobin F0. 54
Thrombin interaction with platelet GpIB: role of the heparin binding domain. 53
Allosteric modulation of BPTI interaction with human alpha- and zeta-thrombin. 52
Fibrinogen-elongated gamma chain inhibits thrombin-induced platelet response, hindering the interaction with different receptors 52
Binding of human alpha-thrombin to platelet GpIb: energetics and functional effects. 51
Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy 51
On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens 50
Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. 47
Measurement of plasma fibrinogen concentration by the prothrombin-time-derived method: applicability and limitations. 47
Current Choices and Management of Treatment in Persons with Severe Hemophilia A without Inhibitors: A Mini‐Delphi Consensus 46
Mechanistic studies on ADAMTS13 catalysis 45
Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy 45
Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia 45
KINETIC ASPECTS OF RELEASE OF FIBRINOPEPTIDES AP AND AY BY HUMAN ALPHA-THROMBIN 44
Fibrinogen-elongated gamma chain inhibits thrombin-induced platelet response, hindering the interaction with different receptors 43
Italian intersociety consensus on DOAC use in internal medicine 42
Do We Need to Define Therapeutic Ranges for Edoxaban Plasma Concentration? 42
The p.P1127S pathogenic variant lowers von Willebrand factor levels through higher affinity for the macrophagic scavenger receptor LRP1: Clinical phenotype and pathogenic mechanisms 40
The use of viscoelastic haemostatic assays in non-cardiac surgical settings: A systematic review and meta-analysis 40
Totale 7.861
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.786
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.786
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020753 0 0 0 0 78 124 127 34 79 71 133 107
2020/2021995 36 112 27 100 150 50 109 19 117 76 166 33
2021/20221.124 83 114 24 62 64 35 34 173 60 54 206 215
2022/20231.973 264 318 165 259 155 233 80 171 230 26 56 16
2023/20241.134 41 316 30 78 49 203 66 61 17 39 102 132
2024/2025553 56 42 190 88 177 0 0 0 0 0 0 0
Totale 8.979